AC Immune SA KOL Webinar Transcript
Good morning, and welcome to the AC Immune KOL webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the AC Immune website following the conclusion of the event.
I'd now like to turn the call over to Gary Waanders, Head of Investor Relations and Communications at AC Immune. Please go ahead, Gary.
Thanks, Tara. It's a pleasure to welcome you all to our webinar today on the topic of Abeta PET imaging and its importance as a surrogate marker of clinical efficacy. Before we begin, I'd like to draw your attention to our disclaimer about our forward-looking statements.
And so today, we'll be hearing from our CEO at AC Immune, Andrea Pfeifer, to present an overview of the company's strategy and pipeline, with a focus on our active immunotherapy platform, particularly as it relates to our anti-Abeta candidate, ACI-24.060. Then we will hear from Professor Victor Villemagne of the University of Pittsburgh, an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |